A Randomized, Double-Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers.
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
publication date
- January 1, 2023